1 DuPont Nutrition & Health, Active Nutrition, Sokeritehtaantie 20, 02460 Kantvik, Finland.
2 INSERM1048, Institut des maladies métaboliques et cardiovasculaires de Rangueil, Rangueil Hospital, 31432 Toulouse, France.
Benef Microbes. 2016 Feb;7(1):11-22. doi: 10.3920/BM2015.0069. Epub 2015 Nov 13.
Changes in the gut microbiota are associated with metabolic disorders, such as overweight and elevated blood glucose. Mouse studies have shown that gut microbiota can regulate metabolism with a mechanism related to gut barrier function. An impaired gut barrier permits the translocation of bacteria and their components which, when in contact with the sub-mucosal immune system, evoke metabolic inflammation and distract signalling in metabolically active tissues. Despite thorough research of the topic in animals, the hypothesis is yet to be proven in humans. Cross-sectional studies have shown that certain bacterial populations - such as Akkermansia muciniphila, Faecalibacterium prausnitzii, Methanobrevibacter smithii and Christensenellaceae - are better represented in lean individuals compared to those who are overweight or metabolically unhealthy. Although these differences reflect those seen in mice, it is possible that they are caused by different dietary or other lifestyle habits. Diet has an indisputable influence on gut microbiota making it very difficult to draw conclusions on microbiota-host interactions from cross-sectional studies. Certain research areas do, however, indicate that gut microbiota could causally influence metabolism. Several studies show that antibiotic use in infancy increases body weight in later childhood. Also, probiotics are emerging as a potential therapy for metabolic syndrome. In fact, a handful of human studies and numerous animal studies show promise for probiotics in reducing blood glucose levels or improving insulin sensitivity. For weight management human evidence is scarcer. Nevertheless, it is becoming increasingly recognised that gut microbiota plays a part regulating metabolism, also in humans, which gives rise to novel opportunities for preventative and treatment strategies.
肠道微生物群的变化与代谢紊乱有关,例如超重和血糖升高。小鼠研究表明,肠道微生物群可以通过与肠道屏障功能相关的机制来调节代谢。肠道屏障受损会允许细菌及其成分易位,当它们与黏膜下免疫系统接触时,会引发代谢炎症,并干扰代谢活跃组织中的信号转导。尽管在动物身上对此进行了深入研究,但这一假设尚未在人类身上得到证实。横断面研究表明,某些细菌种群,如阿克曼氏菌、普拉梭菌、甲烷短杆菌和克里斯滕森氏菌科,在瘦人身上的丰度高于超重或代谢不健康的人。尽管这些差异反映了在小鼠中观察到的差异,但也有可能是由不同的饮食或其他生活方式习惯引起的。饮食对肠道微生物群有不可否认的影响,因此很难从横断面研究中得出关于微生物群与宿主相互作用的结论。然而,某些研究领域确实表明肠道微生物群可能会对代谢产生因果影响。一些研究表明,婴儿期使用抗生素会增加儿童后期的体重。此外,益生菌正成为代谢综合征的一种潜在治疗方法。事实上,一些人体研究和大量动物研究表明益生菌有希望降低血糖水平或改善胰岛素敏感性。对于体重管理,人体证据较少。然而,人们越来越认识到,肠道微生物群在调节代谢中起着一定的作用,这也为预防和治疗策略提供了新的机会。
Proc Nutr Soc. 2010-6-14
Diabetes Metab. 2014-3-14
Nutrients. 2018-11-1
Nutr Hosp. 2015-2-7
Cell Mol Life Sci. 2022-1-19